Woolsey Lab

1.     Cross RW, Turcinovic J, Prasad AN, Borisevich V, Agans KN, Deer DJ, O'Toole R, Dobias NS, Woolsey C, Fenton KA, Geisbert TW. Oral 4`fluorouridine rescues nonhuman primates from advanced Lassa fever. In press Nature.

2.     Woolsey C and Geisbert TW. Marburg Virus Disease: A Comprehensive Review. In press Clinical Microbiology Reviews.

3.     de La Vega MA, Xiii A, Kobinger GP, Woolsey C. Mpox and animal models: Comprehensive evaluation of susceptible species for pathogenesis and drug discovery. In press Emerging Microbes and Infections.

4.     Cross RW, Prasad AN, Turcinovic J, Borisevich V, Agans KN, Woolsey C, Deer DJ, Harrison MB, O'Toole R, Villasante-Tezanos A, Velasquez-Reyes J, Dobias NS, Connor JH, Fenton KA, Geisbert TW. Lassa fever in African green monkeys: Clinical disease and fatal outcome are associated with systemic viral dissemination and inflammation. Cell Rep Med. 2025 Jul 31:102263. doi: 10.1016/j.xcrm.2025.102263. Epub ahead of print. PMID: 40763738.

5.     Pigeaud DD, Fenton KA, Turcinovic J, Borisevich V, Agans KN, Deer DJ, Harrison MB, Fears AC, Dobias NS, Prasad AN, Smith IL, Williams DT, Woolsey CB, Broder CC, Cross RW, Geisbert TW. Experimental challenge of African green monkeys with contemporary Hendra virus isolates produces divergent clinical disease. Emerg Microbes Infect. 2025 Aug 6:2544735. doi: 10.1080/22221751.2025.2544735. Epub ahead of print. PMID: 40768740.

6.     Alvarado AV, Cross RW, Geisbert TW, Woolsey C. Animal Models of Pathogenic New World Arenaviruses. Microorganisms. 2025 Jun 11;13(6):1358. doi: 10.3390/microorganisms13061358. PMID: 40572246; PMCID: PMC12196189.

7.     Prasad AN, Woolsey C, Borisevich V, Agans KN, Deer DJ, Geisbert JB, Harrison MB, Dobias NS, Fenton KA, Cross RW, Geisbert TW. Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus. Nat Commun. 2025 Apr 23;16(1):3824. doi: 10.1038/s41467-025-59168-5. PMID: 40268932; PMCID: PMC12019533.

8.     Johnson DM, Woolsey C, Agans KN, Borisevich V, Prasad AN, Deer DJ, Dobias NS, Fenton KA, Cross RW, Geisbert TW. Pathogenesis of Chapare virus in cynomolgus macaques. EMI Anim Environ. 2025 Jun 11;1(1):2486952. doi: 10.1080/29986990.2025.2486952. PMID: 40740682; PMCID: PMC12306676.

9.     Cooper CL, Morrow G, Yuan M, Postler TS, Neal ML, Cross RW, Woolsey C, Agans KN, Borisevich V, McNamara RP, Atyeo C, Roy V, Germosen D, Hou F, Li SL, Reiserova L, Choi Y, Wilson A, Wagner D, Wallace-Selman O, Carpov A, Geng F, Frederick DJ, DeStefano J, Ercolini AM, Enriquez AS, Hastie KM, Ramos da Silva S, Sayeed E, Coleman JW, Kilianski A, Alter G, Saphire EO, Aitchison JD, Geisbert TW, Gupta SB, Feinberg MB, Parks CL. Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials. EBioMedicine. 2025 Apr;114:105647. doi: 10.1016/j.ebiom.2025.105647. Epub 2025 Mar 28. PMID: 40157130; PMCID: PMC11994357.

10.  Woolsey C, Cross RW, Chu VC, Prasad AN, Agans KN, Borisevich V, Deer DJ, Harrison MB, Martinez JK, Dobias NS, Fenton KA, Cihlar T, Nguyen AQ, Babusis D, Bannister R, Vermillion MS, Geisbert TW. The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection. Sci Adv. 2025 Mar 14;11(11):eadw0659. doi: 10.1126/sciadv.adw0659. Epub 2025 Mar 14. PMID: 40085692; PMCID: PMC11908469.

11.  Cross RW*, Woolsey C*, Prasad AN, Borisevich V, Agans KN, Deer DJ, Harrison MB, Dobias NS, Fenton KA, Cihlar T, Nguyen AQ, Babusis D, Bannister R, Vermillion MS, Chu VC, Geisbert TW. Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates. Nat Med. 2025 Jan 13. doi: 10.1038/s41591-025-03496-y. Epub ahead of print. PMID: 39805309.

12.  Cross RW*, Woolsey C*, Chu VC*, Babusis D, Bannister R, Vermillion MS, Geleziunas R, Barrett KT, Bunyan E, Nguyen AQ, Cihlar T, Porter DP, Prasad AN, Deer DJ, Borisevich V, Agans KN, Martinez J, Harrison MB, Dobias NS, Fenton KA, Bilello JP, Geisbert TW. Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus. Science. 2024 Mar 15;383(6688):eadk6176. doi: 10.1126/science.adk6176. Epub 2024 Mar 15. PMID: 38484056.

13.  Zeitlin L, Cross RW, Woolsey C, West BR, Borisevich V, Agans KN, Prasad AN, Deer DJ, Stuart L, McCavitt-Malvido M, Kim DH, Pettitt J, Crowe JE Jr, Whaley KJ, Veesler D, Dimitrov A, Abelson DM, Geisbert TW, Broder CC. Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates. Sci Transl Med. 2024 Apr 3;16(741):eadl2055. doi: 10.1126/scitranslmed.adl2055. Epub 2024 Apr 3. PMID: 38569014.

14.  Adam A, Woolsey C, Lu H, Plante K, Wallace SM, Rodriguez L, Shinde DP, Cui Y, Franz AWE, Thangamani S, Comer JE, Weaver SC, Wang T. A safe insect-based chikungunya fever vaccine affords rapid and durable protection in cynomolgus macaques. NPJ Vaccines. 2024 Dec 19;9(1):251. doi: 10.1038/s41541-024-01047-z. PMID: 39702442; PMCID: PMC11659317.

15.  de La Vega MA, Xiii A, Massey S, Spengler JR, Kobinger GP, Woolsey C. An update on nonhuman primate usage for drug and vaccine evaluation against filoviruses. Expert Opin Drug Discov. 2024 Aug 18:1-27. doi: 10.1080/17460441.2024.2386100. Epub ahead of print. PMID: 39090822.

16.  Woolsey C, Cross RW, Prasad AN, Agans KN, Borisevich V, Deer DJ, Dobias NS, Fears AC, Harrison MB, Heinrich ML, Fenton KA, Garry RF, Branco LM, Geisbert TW. Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates. Emerg Microbes Infect. 2024 Dec;13(1):2301061. doi: 10.1080/22221751.2023.2301061. Epub 2024 Jan 22. PMID: 38164768; PMCID: PMC10810630.

17.  Woolsey C*, Cross RW*, Fenton KA*, Prasad AN, Borisevich V, Agans KN, Deer DJ, Dobias NS, Fears AC, Heinrich ML, Geisbert JB, Garry RF, Branco LM, Geisbert TW. Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus. Cell Rep Med. 2024 Feb 20;5(2):101392. doi: 10.1016/j.xcrm.2024.101392. Epub 2024 Jan 26. PMID: 38280377.

18.  To A, Wong TAS, Ball AH, Lieberman MM, Yalley-Ogunro J, Cabus M, Nezami S, Paz F, Elyard HA, Borisevich V, Agans KN, Deer DJ, Woolsey C, Cross RW, Geisbert TW, Donini O, Lehrer AT. Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection. Vaccine. 2024 Jan 25;42(3):598-607. doi: 10.1016/j.vaccine.2023.12.053. Epub 2023 Dec 28. PMID: 38158300; PMCID: PMC10872277.

19.  Cross RW, Wiethoff CM, Brown-Augsburger P, Berens S, Blackbourne J, Liu L, Wu X, Tetreault J, Dodd C, Sina R, Witcher DR, Newcomb D, Frost D, Wilcox A, Borisevich V, Agans KN, Woolsey C, Prasad AN, Deer DJ, Geisbert JB, Dobias NS, Fenton KA, Strifler B, Ebert P, Higgs R, Beall A, Chanda S, Riva L, Yin X, Geisbert TW. The Therapeutic Monoclonal Antibody Bamlanivimab Does Not Enhance SARS-CoV-2 Infection by FcR-Mediated Mechanisms. Pathogens. 2023 Nov 30;12(12):1408. doi: 10.3390/pathogens12121408. PMID: 38133292; PMCID: PMC10746090.

20.  Pigeaud DD, Geisbert TW, Woolsey C. Animal Models for Henipavirus Research. Viruses. 2023; 15(10):1980. https://doi.org/10.3390/v15101980

21.  Cross RW, Heinrich ML, Fenton KA, Borisevich V, Agans KN, Prasad AN, Woolsey C, Deer DJ, Dobias NS, Rowland MM, Lathigra R, Borrega R, Geisbert JB, Garry RF, Branco LM, Geisbert TW. A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus. Proc Natl Acad Sci U S A. 2023 Aug 22;120(34):e2304876120. doi: 10.1073/pnas.2304876120. Epub 2023 Aug 17. PMID: 37590417; PMCID: PMC10450431.

22.  Sprecher A, Cross R, Marzi A, Martins KA, Wolfe D, Montgomery JM, Spiropoulou CF, Cihlar T, Ahuka-Mundeke S, Nyhuis T, Teicher C, Crozier I, Strong J, Kobinger G, Woolsey C, Geisbert TW, Feldmann H, Muyembe JJ. Perspectives on Advancing Countermeasures for Filovirus Disease: Report from a Multi-Sector Meeting. J Infect Dis. 2023 Aug 19:jiad354. doi: 10.1093/infdis/jiad354. Epub ahead of print. PMID: 37596837.

23.  Abelson D, Barajas J, Stuart L, Kim D, Marimuthu A, Hu C, Yamamoto B, Ailor E, Whaley KJ, Vu H, Agans KN, Borisevich V, Deer DJ, Dobias NS, Woolsey C, Prasad AN, Peel JE, Lawrence WS, Cross RW, Geisbert TW, Fenton KA, Zeitlin L. Long-term prophylaxis against aerosolized Marburg virus in non-human primates with an afucosylated monoclonal antibody. J Infect Dis. 2023 Jul 20:jiad278. doi: 10.1093/infdis/jiad278. Epub ahead of print. PMID: 37474248.

24.  Prasad AN, Agans KN, Geisbert JB, Borisevich V, Deer DJ, Dobias NS, Comer JE, Woolsey C, Fenton KA, Geisbert TW, Cross RW. Natural history of nonhuman primates after oral exposure to Ebola virus variant Makona. J Infect Dis. 2023 Jun 22:jiad225. doi: 10.1093/infdis/jiad225. Epub ahead of print. PMID: 37348509.

25.  Woolsey C*, Strampe J*, Fenton KA, Agans KN, Martinez J, Borisevich V, Dobias NS, Deer DJ, Geisbert JB, Cross RW, Connor JH, Geisbert TW. A recombinant vesicular stomatitis virus-based vaccine provides postexposure protection against Bundibugyo ebolavirus infection. J Infect Dis. 2023 Jun 8:jiad207. doi: 10.1093/infdis/jiad207. Epub ahead of print. PMID: 37290053.

26.  Woolsey C, Borisevich V, Agans KN, O'Toole R, Fenton KA, Harrison MB, Prasad AN, Deer DJ, Gerardi C, Morrison N, Cross RW, Eldridge JH, Matassov D, Geisbert TW. A highly attenuated pan-filovirus VesiculoVax vaccine rapidly protects nonhuman primates against Marburg virus and three species of Ebolavirus. J Infect Dis. 2023 May 12:jiad157. doi: 10.1093/infdis/jiad157. Epub ahead of print. PMID: 37171813.

27.  Prasad AN, Fenton KA, Agans KN, Borisevich V, Woolsey C, Comer JE, Dobias NS, Peel JE, Deer DJ, Geisbert JB, Lawrence WS, Cross RW, Geisbert TW. Pathogenesis of aerosolized Ebola virus variant Makona in nonhuman primates. J Infect Dis. 2023 May 5:jiad137. doi: 10.1093/infdis/jiad137. Epub ahead of print. PMID: 37145930.

28.  Cross RW, Prasad AN, Woolsey CB, Agans KN, Borisevich V, Dobias NS, Comer JE, Deer DJ, Geisbert JB, Rasmussen AL, Lipkin WI, Fenton KA, Geisbert TW. Natural history of nonhuman primates after conjunctival exposure to Ebola virus. Sci Rep. 2023 Mar 13;13(1):4175. doi: 10.1038/s41598-023-31027-7. PMID: 36914721; PMCID: PMC10011569.

29.  Woolsey C, Borisevich V, Fears AC, Agans KN, Deer DJ, Prasad AN, O'Toole R, Foster SL, Dobias NS, Geisbert JB, Fenton KA, Cross RW, Geisbert TW. Recombinant vesicular stomatitis virus-vectored vaccine induces long-lasting immunity against Nipah virus disease. J Clin Invest. 2023 Feb 1;133(3):e164946. doi: 10.1172/JCI164946. PMID: 36445779; PMCID: PMC9888376.

30.  Woolsey C, Fears AC, Borisevich V, Agans KN, Dobias NS, Prasad AN, Deer DJ, Geisbert JB, Fenton KA, Geisbert TW, Cross RW. Natural history of Sudan ebolavirus infection in rhesus and cynomolgus macaques. Emerg Microbes Infect. 2022 Dec;11(1):1635-1646. doi: 10.1080/22221751.2022.2086072. PMID: 35657325; PMCID: PMC9225728.

31.  Cross RW, Longini IM, Becker S, Bok K, Boucher D, Carroll MW, Díaz JV, Dowling WE, Draghia-Akli R, Duworko JT, Dye JM, Egan MA, Fast P, Finan A, Finch C, Fleming TR, Fusco J, Geisbert TW, Griffiths A, Günther S, Hensley LE, Honko A, Hunegnaw R, Jakubik J, Ledgerwood J, Luhn K, Matassov D, Meshulam J, Nelson EV, Parks CL, Rustomjee R, Safronetz D, Schwartz LM, Smith D, Smock P, Sow Y, Spiropoulou CF, Sullivan NJ, Warfield KL, Wolfe D, Woolsey C, Zahn R, Henao-Restrepo AM, Muñoz-Fontela C, Marzi A. An introduction to the Marburg virus vaccine consortium, MARVAC. PLoS Pathog. 2022 Oct 13;18(10):e1010805. doi: 10.1371/journal.ppat.1010805. PMID: 36227853; PMCID: PMC9560149.

32.  Cross RW*, Woolsey C*, Prasad AN, Borisevich V, Agans KN, Deer DJ, Geisbert JB, Dobias NS, Fenton KA, Geisbert TW. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever. Cell Rep. 2022 Jul 19;40(3):111094. doi: 10.1016/j.celrep.2022.111094. PMID: 35858566.

33.  Woolsey C, Cross RW, Agans KN, Borisevich V, Deer DJ, Geisbert JB, Gerardi C, Latham TE, Fenton KA, Egan MA, Eldridge JH, Geisbert TW, Matassov D. A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge. PLoS Negl Trop Dis. 2022 May 27;16(5):e0010433. doi: 10.1371/journal.pntd.0010433. PMID: 35622847; PMCID: PMC9182267.

34.  Cross RW, Bornholdt ZA, Prasad AN, Woolsey C, Borisevich V, Agans KN, Deer DJ, Abelson DM, Kim DH, Shestowsky WS, Campbell LA, Bunyan E, Geisbert JB, Dobias NS, Fenton KA, Porter DP, Zeitlin L, Geisbert TW. Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease. JCI Insight. 2022 May 23;7(10):e159090. doi: 10.1172/jci.insight.159090. PMID: 35413016; PMCID: PMC9220838.

35.  Foster SL*, Woolsey C*, Borisevich V, Agans KN, Prasad AN, Deer DJ, Geisbert JB, Dobias NS, Fenton KA, Cross RW, Geisbert TW. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease. Proc Natl Acad Sci U S A. 2022 Mar 22;119(12):e2200065119. doi: 10.1073/pnas.2200065119. Epub 2022 Mar 14. PMID: 35286211; PMCID: PMC8944267.

36.  Woolsey C, Geisbert TW. Current state of Ebola virus vaccines: A snapshot. PLoS Pathog. 2021 Dec 9;17(12):e1010078. doi: 10.1371/journal.ppat.1010078. PMID: 34882741; PMCID: PMC8659338.

37.  Woolsey C, Borisevich V, Agans KN, Fenton KA, Cross RW, Geisbert TW. Bundibugyo ebolavirus Survival Is Associated with Early Activation of Adaptive Immunity and Reduced Myeloid-Derived Suppressor Cell Signaling. mBio. 2021 Aug 31;12(4):e0151721. doi: 10.1128/mBio.01517-21. Epub 2021 Aug 10. PMID: 34372693; PMCID: PMC8406165.

38.  Pinski A*, Woolsey C*, Jankeel A, Cross R, Basler CF, Geisbert T, Messaoudi I. Transcriptional Analysis of Lymphoid Tissues from Infected Nonhuman Primates Reveals the Basis for Attenuation and Immunogenicity of an Ebola Virus Encoding a Mutant VP35 Protein. J Virol. 2021 Feb 24;95(6):e01995-20. doi: 10.1128/JVI.01995-20. PMID: 33408171; PMCID: PMC8094945.

39.  Cross RW, Prasad AN, Borisevich V, Woolsey C, Agans KN, Deer DJ, Dobias NS, Geisbert JB, Fenton KA, Geisbert TW. Use of convalescent serum reduces severity of COVID-19 in nonhuman primates. Cell Rep. 2021 Mar 9;34(10):108837. doi: 10.1016/j.celrep.2021.108837. Epub 2021 Feb 23. PMID: 33662255; PMCID: PMC7901292.

40.  Woolsey C, Borisevich V, Prasad AN, Agans KN, Deer DJ, Dobias NS, Heymann JC, Foster SL, Levine CB, Medina L, Melody K, Geisbert JB, Fenton KA, Geisbert TW, Cross RW. Establishment of an African green monkey model for COVID-19 and protection against re-infection. Nat Immunol. 2021 Jan;22(1):86-98. doi: 10.1038/s41590-020-00835-8. Epub 2020 Nov 24. PMID: 33235385; PMCID: PMC7790436.